
    
      The study will be conducted in 2 phases:

      In the single ascending dose (SAD) phase, up to approximately 42 healthy adult participants
      will be sequentially enrolled into up to approximately 7 cohorts. In the multiple-dose (MD)
      phase, approximately 12 patients with mild to moderate Alzheimer's disease will be enrolled
      in one cohort.
    
  